Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax- JE) as a live, attenuated vaccine candidate against Japanese encephalitis

Virology

Volumn 257, Issue 2, 1999, Pages 363-372

  Guirakhoo, F ^a   Zhang, Z X ^a   Chambers, T J ^c   Delagrave, S ^a   Arroyo, J ^a   Barrett, A D T ^b   Monath, T P ^a  

^a Acambis   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c SAINT LOUIS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CULTURE; CHIMERA; ENVELOPE GENE; EPIDEMIC ENCEPHALITIS; GENE INSERTION; GENETIC STABILITY; JAPANESE ENCEPHALITIS VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINE PRODUCTION; VIRUS CORE; VIRUS RECOMBINANT; VIRUS VIRULENCE; YELLOW FEVER FLAVIVIRUS;

ANIMALIA; FLAVIVIRUS; JAPANESE ENCEPHALITIS VIRUS; YELLOW FEVER VIRUS;

EID: 0033541937     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1999.9695     Document Type: Article

References (34)

1. Aihara H., Takasaki T., Matsutani T., Suzuki R., Kurane I. Establishment and characterization of Japanese encephalitis virus-specific, human CD4+ T-cell clones: Flavivirus cross-reactivity, protein recognition, and cytotoxic activity. J. Virol. 72:1998;8032-8036.
2. Aihara S., Chunming R., Yong-Xin Y. Identification of mutation that occurred on the genome of Japanese encephalitis virus during attenuation process. Virus Genes. 5:1991;95-109.
3. Barrett A. D. T. Yellow fever vaccine. Biologicals. 25:1997;17-26.
4. Chambers T. J., Nestorowicz A., Mason P. W., Rice C. M. Yellow fever/Japanese encephalitis chimeric viruses: Construction and biological properties. J. Virol. 73:1999;3095-3101.
5. Chumakov K., Norwood L., Parker M., Dragunsky E., Ran Y., Levenbook I. RNA sequence variants in live poliovirus vaccine and their relation to neurovirulence. J. Virol. 66:1992;966-970.
6. Collier W. A., De Roever-Bonnet H., Hoekstra J. A neurotropic variety of the vaccine strain 17D. Trop. Geogr. Med. 11:1959;80.
7. Despres P., Dietrich J., Girard M., Bouloy M. Recombinant baculovirus expressing yellow fever virus E and NS1 proteins elicit protective immunity in mice. J Gen. Virol. 72:1991;2811-2816.
8. Duarte dos Santos C. N., Post P. R., Carvalho R., Rice C. M., Galler R. Complete nucleotide sequence of yellow fever virus vaccine strains 17DD and 17D-213. Virus Res. 35:1995;35-41.
9. Dupuy A., Despres P., Cahour A., Girard M., Bouloy M. Nucleotide sequence comparison of the genome of two 17D-204 yellow fever vaccines. Nucleic Acids Res. 17:1989;3989.
10. Fitzgeorge R., Bradish C. J. The in vivo differentiation of strains of yellow fever virus in mice. J. Gen. Virol. 46:1980;1.
11. Halstead S., Eckels K., Putavatana R., Key Larson L., Marchette N. Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. IV. Characterization of a vaccine candidate in fetal rhesus lung cells. Am. Soc. Trop. Med. Hyg. 33:1984;679-683.
12. Hennessy S., Zhengle l., Tsai T., Strom B., Chao-Min W., Hui-Lian L., Tai-Xiang W. Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): A case-control study. Lancet. 347:1996;1583-1586.
13. Hoke C., Nisalak A., Sangawhipa N., Jatanasen S., Laorakapongse T., Innis B. Protection against Japanese encephalitis by inactivated vaccines. N. Engl. J. Med. 319:1988;608-614.
14. Konishi E., Sane Win K., Kurane I., Mason P., Shope R., Ennis F. Particulate vaccine candidate for Japanese encephalitis induces long-lasting memory T lymphocytes in mice. Vaccine. 15:1997;281-286.
15. Konishi E., Yamaoka M., Sane Win K., Kurane I., Mason P. W. Induction of protective immunity against Japanese encephalitis with a plasmid encoding Japanese encephalitis virus premembrane and envelope genes. J. Virol. 72:1998;4925-4930.
16. Lobigs M., Arthur C., Muellbacher A., Blanden R. The flavivirus nonstructural protein NS3 is a dominant source of cytotoxic T cell peptide determinants. Virlogy. 202:1994;195-201.
17. Marcus P. I., Sekellick M. J. Interferon induction by viruses. XVI. 2-Aminopurine block selectively and reversibly an early stage in interferon induction. J. Gen. Virol. 69:1988;1637-1645.
18. McAda P., Mason P., Schmaljohn C., Dalrymple J., Mason T., Fourinier M. Partial nucleotide sequence of Japanese encephalitis virus genome. Virology. 158:1987;348-360.
19. Monath, T. P. 1999, Yellow fever, In, Vaccines, W.B. Saunders, Phila, PA.
20. Monath T. P., Heinz F. X. Flaviviruses. Fields B. N., Knipe D. M., Howley P. M. Fields Virology. 1996;961-1034 Lippincott-Raven Publishers, Philadelphia.
21. Monath T. P., Soike K., Levenbook I, Zhang Z-X, Arroyo J., Delagrave S., Myers G., Barrett A. D. T., Shope R. E., Chambers T. J., Guirakhoo F. Recombinant, chimeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) and the capsid and nonstructural genes of yellow fever (17D) is safe, immunogenic and protective in non-human primates. Vaccine. 17:1999;1869-1882.
22. Ni H., Burns J., Chang G. J., Zhang M. J., Wills M. R., Trent D. W., Sanders P. J., Barrett A. D. T. Comparison of nucleotide and deduced amino acid sequence of the 5 non-coding region and structural protein genes of the wild-type Japanese encephalitis virus strain SA14 and its attenuated vaccine derivatives. J. Gen. Virol. 75:1994;1505-1510.
23. Ni H., Chang G.-J., Xie H., Trent D. W., Barrett A. D. T. Molecular basis of attenuation of neurovirulence of wild-type Japanese encephalitis virus strain SA14. J. Gen. Virol. 76:1995;409-413.
24. Nitayaphan S., Grant J., Chang G. J., Trent D. W. Nucleotide sequence of the virulent SA-14 strain of Japanese encephalitis virus and its attenuated vaccine derivatives, SA14-14-2. Virology. 177:1990;541-552.
25. Post P. R., Santos C. N., Carvalho R., Cruz A. C., Rice C. M., Galler R. Heterogeneity in envelope protein sequence and N-linked glycosylation among yellow fever virus vaccine strains. Virology. 188:1992;160-167.
26. Putnak R., Schlesinger J. Protection of mice against yellow fever virus encephalitis by immunization with a vaccinia virus recombinant encoding the yellow fever virus non-structural proteins, NS1, NS2a and NS2b. J. Gen. Virol. 71:1990;1697-1702.
27. Rice C. M., Grakoui A, Galler R., Chambers T. J. Transcription of infectious yellow fever RNA from full-length cDNA templates produced by in vitro ligation. New Biol. 1:1989;285-296.
28. Rice C. M., Lenches E. M., Eddy S. R., Shin S. J., Sheets R. L., Strauss J. H. Nucleotide sequence of yellow fever virus: Implication for flavivirus gene expression and evolution. Science. 229:1985;726-733.
29. Schlesinger J., Foltzer M., Chapman S. The Fc portion of antibody to yellow fever virus NS1 is a determinant of protection against yellow fever encephalitis in mice. Virology. 192:1993;132-141.
30. Sekellick M. J., Marcus P. I. Interferon induction by viruses. XIV. Development of interferon inducibility and its inhibition in chick embryo cells "aged"in vitro. J. Interferon Res. 5:1985;651-667.
31. Sumiyoshi H., Tignor G. H., Shope R. E. Characterization of a highly attenuated Japanese encephalitis virus generated from molecularly cloned cDNA. J. Infect. Dis. 171:1995;1144-1151.
32. Theiler M., Smith H. The use of yellow fever virus modified byin vitro. J. Exp. Med. 65:1937;787-800.
33. Weekly Epidemiological Record. No. 44. 73:1998;337-344.
34. Xie H., Cass A. R., Barrett A. D. T. Yellow fever 17D vaccine virus isolated from healthy vaccinees accumulates very few mutations. Virus Res. 55:1998;93-99.